Functional Neurology 2012-01-01

Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.

Giovanni Abbruzzese, Paolo Barone, Ubaldo Bonuccelli, Leonardo Lopiano, Angelo Antonini

Index: Funct. Neurol. 27(3) , 147-54, (2012)

Full Text: HTML

Abstract

Long-term oral therapy with levodopa is associated with the development of motor fluctuations and dyskinesia in a large percentage of patients with Parkinson's disease (PD). Motor complications are associated with a number of non-motor symptoms and have a negative impact on disability and quality of life. There are three therapeutic options available for the management of patients at this advanced stage: high frequency deep brain stimulation, continuous subcutaneous infusion of apomorphine, and continuous intestinal infusion of levodopa/carbidopa. On the basis of published data and in consideration of the risk-benefit profile of current therapeutic strategies, we here propose an algorithm to help clinicians select the most suitable treatment option for patients with advanced PD.

Related Compounds

  • Carbidopa monohydr...
  • Carbidopa

Related Articles:

[(11)C]5-HTP and microPET are not suitable for pharmacodynamic studies in the rodent brain.

2014-01-01

[J. Cereb. Blood Flow Metab. 34(1) , 118-25, (2014)]

Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems.

2014-12-01

[Eur. J. Drug Metab. Pharmacokinet. 39(4) , 237-42, (2014)]

Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.

2014-11-01

[Cancer Res. 74(21) , 6205-15, (2014)]

[Scleroderma-like syndrome with bullous morphea during treatment with 5-hydroxytryptophan, carbidopa and flunitrazepam].

1992-01-01

[Ann. Dermatol. Venereol. 119(3) , 209-11, (1992)]

Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.

2013-02-25

[Brain Res. 1497 , 1-14, (2013)]

More Articles...